Advertisement
Prior to his appointment as Senior Vice President of Business Strategiesin July 2007, Mr. Singh served as Vice President - Sales and Marketing(September 2003 to July 2007) and National Sales and Marketing Manager(September 2000 to September 2003) of the Company. From May 1998 to September2000, Mr. Singh was the Manager of Bulk Drugs for Sun PharmaceuticalIndustries Limited.
Advertisement
Daniel H. Movens, the Company's Chief Executive Officer, noted that Dr.Doshi had an extensive history of dedicated service to the Company statingthat "Mr. Doshi has provided invaluable service to the Company as an executiveofficer, including CEO, and as a Director, since 2001. His efforts greatlycontributed to the success we have achieved." Mr. Doshi continues to serve asan Executive Director for Sun Pharmaceutical Industries Inc.
Mr. Movens continued, "We are very pleased to welcome Mr. Singh to theBoard. His experience, depth of knowledge and accomplished background shouldprovide us with good guidance into the foreseeable future. We are certainthat he will bring to the Board the same energy and sound judgment that he hasshown as an executive officer of the Company."
Safe Harbor: This news release contains forward-looking statements madepursuant to the safe-harbor provisions of the Private Securities LitigationReform Act of 1995. Such statements are based on management's currentexpectations and are subject to risks and uncertainties that could causeactual results to differ materially from those described in theforward-looking statements. These risks and uncertainties are contained inthe Corporation's filings with the Securities and Exchange Commission,including Item 1A to the Corporation's annual report on Form 10-K, andinclude, but are not limited to: information of a preliminary nature that maybe subject to adjustment, potentially not obtaining or delay in obtaining FDAapproval for new products, governmental restrictions on the sale of certainproducts, development by competitors of new or superior products or lessexpensive products or new technology for the production of products, the entryinto the market of new competitors, market and customer acceptance and demandfor new pharmaceutical products, availability of raw materials, timing andsuccess of product development and launches, dependence on few productsgenerating majority of sales, product liability claims for which the Companymay be inadequately insured, and other risks identified in this report andfrom time to time in our periodic reports and registration statements. Theseforward-looking statements represent our judgment as of the date of thisreport. We disclaim, however, any intent or obligation to update ourforward-looking statements.
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
